Publication details

Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

Authors

MUSTO Pellegrino SALMANTON-GARCIA Jon SGHERZA Nicola BERGANTIM Rui FARINA Francesca GLENTHOJ Andreas GULDANE Cengiz Seval WEINBERGEROVÁ Barbora BONUOMO Valentina BILGIN Yavuz M JAAP van Doesum JAKSIC Ozren VISEK Benjamin FALCES-ROMERO Iker MARCHETTI Monia DAVILA-VALLS Julio MARTIN-PEREZ Sonia NUCCI Marcio LOPEZ-GARCIA Alberto ITRI Federico BUQUICCHIO Caterina VERGA Luisa PIUKOVICS Klara NAVRATIL Milan COLLINS Graham P JIMENEZ Moraima FRACCHIOLLA Nicola S LABRADOR Jorge PREZIOSO Lucia ROSSI Elena COLOVIC Natasha MEERS Stef KULASEKARARAJ Austin CUCCARO Annarosa BLENNOW Ola VALKOVIC Toni SILI Uluhan LEDOUX Marie-Pierre BATINIC Josip PASSAMONTI Francesco MACHADO Marina DUARTE Rafael F POULSEN Christian Bjorn MENDEZ Gustavo-Adolfo ESPIGADO Ildefonso DEMIRKAN Fatih CERNAN Martin CATTANEO Chiara PETZER Verena MAGLIANO Gabriele GARCIA-VIDAL Carolina EL-ASHWAH Shaimaa GOMES-DA-SILVA Maria VENA Antonio ORMAZABAL-VELEZ Irati JENS van Praet DARGENIO Michelina DE-RAMON Cristina ILARIA Del Principe Maria MARQUES-DE-ALMEIDA Joyce WOLF Dominik SZOTKOWSKI Tomas OBR Ales COLAK Goekce Melis NORDLANDER Anna IZUZQUIZA Macarena CABIRTA Alba ZAMBROTTA Giovanni Paolo Maria CORDOBA Raul ZAK Pavel AMMATUNA Emanuele MAYER Jiri ILHAN Osman GARCIA-SANZ Ramon QUATTRONE Martina ARELLANO Elena NUNES-RODRIGUES Raquel EMARAH Ziad AIELLO Tommaso Francesco HANAKOVA Michaela RACIL Zdenek BAVASTRO Martina LIMONGELLI Alessandro RAHIMLI Laman MARCHESI Francesco CORNELY Oliver A PAGANO Livio

Year of publication 2024
Type Article in Periodical
Magazine / Source Hematological Oncology
MU Faculty or unit

Faculty of Medicine

Citation
Web https://onlinelibrary.wiley.com/doi/10.1002/hon.3240
Doi http://dx.doi.org/10.1002/hon.3240
Keywords COVID-19; hematological malignancy; multiple myeloma; SARS-CoV-2
Description Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 x 109/L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.

You are running an old browser version. We recommend updating your browser to its latest version.

More info